The role of 3-O-methyldopa in the side effects of L-dopa

Neurochemical Research

Volumn 33, Issue 3, 2008, Pages 401-411

  Lee, Eun Sook Y ^a   Chen, Hongtao ^a   King, Jennifer ^a   Charlton, Clivel ^a  

^a MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

3 O methyldopa; L dopa; Locomotor activity; Oxidative stress; Parkinson's disease

Indexed keywords

3 O METHYLDOPA; ADENOSINE; ALPHA TOCOPHEROL; CATECHOLAMINE; DOPAMINE; DOPAMINE TRANSPORTER; HOMOCYSTEINE; LEVODOPA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN; BRAIN MEMBRANE; CATECHOLAMINE BRAIN LEVEL; CATECHOLAMINE NERVE CELL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; LOCOMOTION; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOTOR DYSFUNCTION; NERVE CELL; NERVE CELL LESION; NEUROCHEMISTRY; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; ANTIPARKINSON AGENTS; BRAIN CHEMISTRY; CATECHOLAMINES; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; DOPAMINE ANTAGONISTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; LEVODOPA; MALE; MEMBRANE POTENTIALS; MITOCHONDRIAL MEMBRANES; MOTOR ACTIVITY; PC12 CELLS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RECEPTORS, DOPAMINE D1; SYNAPTIC TRANSMISSION; TYROSINE;

RATTUS;

EID: 38949133757     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-007-9442-6     Document Type: Article

References (49)

1. Muenter MD, Sharpless NS, Tyce GM (1972) Plasma 3-0-methyldopa in l-dopa therapy of Parkinson's disease. Mayo Clin Proc 47:389-395
2. Sharpless NS, Muenter MD, Tyce GM et al (1972) 3-methoxy-4- hydroxyphenylalanine (3-O-methyldopa) in plasma during oral l-dopa therapy of patients with Parkinson's disease. Clin Chim Acta 37:359-369
3. Gervas JJ, Muradas V, Bazan E et al (1983) Effects of 3-OM-dopa on monoamine metabolism in rat brain. Neurology 33:278-282
4. Tohgi H, Abe T, Takahashi S (1991b) Concentrations of tyrosine, l-dihydroxyphenylalanine, dopamine, and 3-O-methyldopa in the cerebrospinal fluid of Parkinson's disease. Neurosci Lett 127:212-214
5. Miller JW, Shukitt-Hale B, Villalobos-Molina R et al (1997) Effect of l-Dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin Neuropharmacol 20:55-66
6. Kuruma I, Bartholini G, Tissot R et al (1971) The metabolism of l-3-O-methyldopa, a precursor of dopa in man. Clin Pharmacol Ther 12:678-82
7. Marion MH, Stocchi F, Quinn NP et al (1986) Repeated levodopa infusions in fluctuating Parkinson's disease: clinical and pharmacokinetic data. Clin Neuropharmacol 9:165-181
8. Marsden CD (1994) Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol Suppl 2:S32-S44
9. Feuerstein C, Serre F, Gavend M et al (1977a) Plasma O-methyldopa in levodopa-induced dyskinesias. A bioclinical investigation. Acta Neurol Scand 56:508-524
10. Feuerstein C, Tauche M, Serre F et al (1977b) Does O-methyl-dopa play a role in levodopa-induced dyskinesias. Acta Neurol Scand 56:79-82
11. Mena MA, Muradas V, Bazan E et al (1987) Pharmacokinetics of l-dopa in patients with Parkinson's disease. Adv Neurol 45:481-486
12. Blandini F, Nappi G, Fancellu R et al (2003) Modifications of plasma and platelet levels of l-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease. J Neural Transm 110:911-922
13. Tohgi H, Abe T, Kikuchi T et al (1991a) The significance of 3-O-methyldopa concentrations in the cerebrospinal fluid in the pathogenesis of wearing-off phenomenon in Parkinson's disease. Neurosci Lett 132:19-22
14. Fabbrini G, Juncos JL, Mouradian MM et al (1987) 3-O-methyldopa and motor fluctuations in Parkinson's disease. Neurology 37:856-859
15. Soares-da-Silva P, Parada A, Serrao P (2000) The O-methylated derivative of l-DOPA, 3-O-methyl-l-DOPA, fails to inhibit neuronal and non-neuronal aromatic l-amino acid decarboxylase. Brain Res 863:293-297
16. Reches A, Fahn S (1982) 3-O-methyldopa blocks dopa metabolism in rat corpus striatum. Ann Neurol 12:267-271
17. Benetello P, Furlanut M, Fortunato M et al (1997) Levodopa and 3-O-methyldopa in cerebrospinal fluid after levodopa-carbidopa association. Pharmacol Res 35:313-315
18. Cheng H, Gomes-Trolin C, Aquilonius SM et al (1997) Levels of l-methionine S-adenosyltransferase activity in erythrocytes and concentrations of S-adenosylmethionine and S-adenosylhomocysteine in whole blood of patients with Parkinson's disease. Exp Neurol 145:580-585
19. Zhao WQ, Latinwo L, Liu XX et al (2001) l-dopa upregulates the expression and activities of methionine adenosyl transferase and catechol-O- methyltransferase. Exp Neurol 171:127-138
20. Chang WY, Webster RA (1995) Effects of 3-O-methyl on l-dopa-facilitated synthesis and efflux of dopamine from rat striatal slices. Br J Pharmacol 116:2637-2640
21. Mena MA, Pardo B, Paino CL et al (1993) Levodopa toxicity in foetal rat midbrain neurons in culture: modulation by ascorbic acid. Neuroreport 4:438-440
22. Mena MA, Casarejos MJ, Carazo A et al (1996) Glia conditioned medium protects fetal rat midbrain neurones in culture from l-DOPA toxicity. Neuroreport 7:441-445
23. Datla KP, Blunt SB, Dexter DT (2001) Chronic l-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions. Mov Disord 16:424-434
24. Melamed E, Offen D, Shirvan A et al (1998) Levodopa toxicity and apoptosis. Ann Neurol 44:S149-S154
25. Murer MG, Dziewczapolski G, Menalled LB et al (1998) Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 43:561-575
26. Walkinshaw G, Waters CM (1995) Induction of apoptosis in catecholaminergic PC12 cells by l-DOPA. Implications for the treatment of Parkinson's disease. J Clin Invest 95:2458-2464
27. Müller T, Woitalla D, Fowler B et al (2002) 3-OMD and homocysteine plasma levels in parkinsonian patients. J Neural Transm 109:175-179
28. Müller T, Woitalla D, Hauptmann B et al (2001) Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease. Neurosci Lett 308:54-56
29. Lee ES, Chen H, Soliman KF et al (2005) Effects of homocysteine on the dopaminergic system and behavior in rodents. Neurotoxicology 26:361-371
30. Spencer JP, Jenner A, Aruoma OI et al (1994) Intense oxidative DNA damage promoted by l-dopa and its metabolites. Implications for neurodegenerative disease. FEBS Lett 353:246-250
31. Martignoni E, Blandini F, Godi L et al (1999) Peripheral markers of oxidative stress in Parkinson's disease. The role of l-DOPA. Free Radic Biol Med 27:428-437
32. Blandini F, Martignoni E, Ricotti R et al (1999) Determination of hydroxyl free radical formation in human platelets using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Sci Appl 732:213-220
33. Lee JJ, Kim YM, Yin SY et al (2003) Aggravation of l-DOPA-induced neurotoxicity by tetrahydropapaveroline in PC12 cells. Biochem Pharmacol 66:1787-1795
34. Lowry CA, Renner KJ, Moore FL (1996) Catecholamines and indoleamines in the central nervous system of a urodele amphibian: a microdissection study with emphasis on the distribution of epinephrine. Brain Behav Evol 48:70-93
35. 3H]SCH 23390, a selective D1 receptor antagonist ligand, in rat striatum. Life Sci 35:1885-1893
36. Woodgate A, MacGibbon G, Walton M et al (1999) The toxicity of 6-hydroxydopamine on PC12 and P19 cells. Brain Res Mol Brain Res 69:84-92
37. Fu W, Luo H, Parthasarathy S et al (1998) Catecholamines potentiate amyloid beta-peptide neurotoxicity: involvement of oxidative stress, mitochondrial dysfunction, and perturbed calcium homeostasis. Neurobiol Dis 5:229-243
38. Palmeira CM, Moreno AJ, Madeira VM et al (1996) Continuous monitoring of mitochondrial membrane potential in hepatocyte cell suspensions. J Pharmacol Toxicol Methods 35:35-43
39. + on membrane permeability in brain mitochondria and cell viability in PC12 cells. Neurochem Int 40:361-369
40. Reilly DK, Rivera-Calimlim L, Van Dyke D (1980) Catechol-O- methyltransferase activity: a determinant of levodopa response. Clin Pharmacol Ther 28:278-286
41. Rivera-Calimlim L, Tandon D, Anderson F et al (1977) The clinical picture and plasma levodopa metabolite profile of parkinsonian nonresponders. Treatment with levodopa and decarboxylase inhibitor. Arch Neurol 34:228-232
42. Gomes P, Soares-da-Silva P (1999) Interaction between l-DOPA and 3-O-methyl-l-DOPA for transport in immortalised rat capillary cerebral endothelial cells. Neuropharmacology 38:1371-1380
43. Himori N, Tanaka Y, Kurasawa M et al (1994) 3-O-methyldopa attenuates the effects of Madopar on the haloperidol-induced cataleptic behavior and the locomotor activity in the mouse. Pharmacology 48:226-233
44. Greene LA, Rein G (1977) Release of (3H)norepinephrine from a clonal line of pheochromocytoma cells (PC12) by nicotinic cholinergic stimulation. Brain Res 138:521-528
45. Schubert D, Klier FG (1977) Storage and release of acetylcholine by a clonal cell line. Proc Natl Acad Sci USA 74:5184-5188
46. Rebois RV, Reynolds EE, Toll L et al (1980) Storage of dopamine and acetylcholine in granules of PC12, a clonal pheochromocytoma cell line. Biochemistry 19:1240-1248
47. Greene LA, Tischler AS (1976) Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci USA 73:2424-2428
48. Basma AN, Morris EJ, Nicklas WJ, Geller HM (1995) l-dopa cytotoxicity to PC12 cells in culture is via its autoxidation. J Neurochem 64:825-832
49. + in PC12 cells: insights into potential neurotoxicants in Parkinson's disease. J Neurochem 62:1503-1510